Valuation: Indivior PLC

Capitalization 1.76B 1.53B 1.44B 1.31B 2.42B 152B 2.72B 17.03B 6.52B 69.82B 6.6B 6.46B 257B P/E ratio 2025 *
13.1x
P/E ratio 2026 * 11.4x
Enterprise value 1.69B 1.47B 1.38B 1.25B 2.32B 146B 2.62B 16.35B 6.26B 67.07B 6.34B 6.21B 247B EV / Sales 2025 *
1.64x
EV / Sales 2026 * 1.38x
Free-Float
96.11%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.95%
1 week+2.15%
Current month+10.85%
1 month+23.76%
3 months+38.04%
6 months+14.49%
Current year+2.25%
More quotes
1 week 1,008
Extreme 1008
1,070
1 month 817
Extreme 817
1,070
Current year 598.5
Extreme 598.5
1,070
1 year 554.5
Extreme 554.5
1,340
3 years 554.5
Extreme 554.5
2,020
5 years 335
Extreme 335
2,020
10 years 104.9
Extreme 104.9
2,523
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 -
Director of Finance/CFO 49 2020-06-28
Chief Operating Officer 44 2024-10-31
Director TitleAgeSince
Director/Board Member 58 2021-03-23
Director/Board Member 62 2021-03-23
Director/Board Member 65 2022-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.95%+2.15%-18.52%-25.85% 1.76B
+1.24%-3.92%-33.79%-30.06% 55.29B
+0.12%-0.30%-7.73%-15.12% 8.91B
-0.64%-2.17%+3.83%+19.64% 6.51B
+3.07%-2.16%+33.42%+110.02% 5.65B
+2.99%+2.88%+20.96%+37.83% 5.31B
-1.24%-13.37%+55.19%-6.97% 3.22B
-2.06%+0.78%+20.45%+19.47% 2.02B
-0.10%-3.42%-0.57%+14.44% 1.95B
-0.95%-2.04%-58.69%-17.34% 1.72B
Average +0.44%-2.23%+1.45%+10.61% 9.23B
Weighted average by Cap. +1.00%-3.05%-16.55%-9.49%
See all sector performances

Financials

2025 *2026 *
Net sales 1.03B 895M 843M 766M 1.42B 89.36B 1.6B 9.98B 3.82B 40.94B 3.87B 3.79B 150B 1.06B 921M 868M 788M 1.46B 91.99B 1.64B 10.28B 3.93B 42.14B 3.99B 3.9B 155B
Net income 140M 122M 115M 104M 193M 12.17B 217M 1.36B 520M 5.57B 527M 516M 20.49B 162M 140M 132M 120M 222M 13.99B 250M 1.56B 598M 6.41B 606M 593M 23.56B
Net Debt -69.36M -60.16M -56.67M -51.49M -95.26M -6.01B -107M -671M -257M -2.75B -260M -255M -10.12B -291M -252M -237M -216M -399M -25.17B -450M -2.81B -1.08B -11.53B -1.09B -1.07B -42.38B
More financial data * Estimated data
Logo Indivior PLC
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Employees
1,041
More about the company
Date Price Change Volume
25-06-20 1,047.00 p +1.95% 414,902
25-06-19 1,027.00 p -1.15% 84,613
25-06-18 1,039.00 p +0.97% 156,303
25-06-17 1,029.00 p -1.06% 295,805
25-06-16 1,040.00 p +1.46% 540,190

Delayed Quote London S.E., June 20, 2025 at 11:35 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.10USD
Average target price
14.60USD
Spread / Average Target
+3.50%
Consensus

Quarterly revenue - Rate of surprise